A Revolutionary Way to Treat Cancer

• Expert in the discovery, development, and translation of novel therapies across diverse therapeutic modalities
• Deep background in immunology and the tumor microenvironment
• Broad therapeutic domain expertise, including oncology, immunology, personalized medicine, and infectious diseases
• Part of teams that developed the first-in-human drug candidates, including small molecule STING agonists and personalized cancer neoantigen vaccine
• Co-authored more than 16 scientific papers and inventor on 3 issued U.S. patents and multiple pending applications
• Formerly Director of Discovery Biology at RAPT Therapeutics
• Formerly Senior Scientist and Head of Biochemistry at Aduro Biotech
• Received his B.S. in Plant Sciences from the University of California, Santa Cruz
• Received his PhD in Molecular and Cell Biology from the University of California, Berkeley
• A Co-inventor of the Company's Universal Cancer Treatment platform

• Expert computational biologist using next generation sequencing data to identify new drug targets and biomarkers of response to cancer therapeutics
• Formerly Bioinformatician at Xenter Medical Technologies
• Formerly Computational Scientist at RAPT Therapeutics
• Invented software to improve cancer antigen detection
• Invented a gene-signature approach to select treatment for breast cancer
• Received his B.S in Bioinformatics from Brigham Young University
• Received his PhD in Cancer Biology with an emphasis in Bioinformatics from the University of Arizona
• A Co-inventor of the Company's Universal Cancer Treatment platform

Sumant Ramachandra serves as an Independent Director on the Board of Lyell Immunopharma (“Lyell”), following Lyell’s acquisition of ImmPACT Bio (“ImmPACT”) in October 2024. As CEO of ImmPACT from November 2021 until its acquisition, he led capital raises, secured clinical grants, and built a team that achieved FDA clearance for three Investigational New Drug (IND) applications, established manufacturing capabilities, and advanced multiple clinical studies.

In addition, Dr. Ramachandra currently serves as an advisor to private equity funds on companies in the pharmaceuticals, biotechnology, and medical devices/software spaces.
Previously, Dr. Ramachandra served as Chief Science, Technology, and Medical Officer at Baxter International, starting in June 2017. He was also appointed President of Baxter Pharmaceuticals in 2019. Prior to Baxter, he held the role of Senior Vice President, Head of Research & Development, at Pfizer Essential Health, and served as Chief Scientific Officer at Hospira from 2008 until Pfizer acquired Hospira in 2015. Earlier in his career, Dr. Ramachandra held senior roles at Pfizer and Merck & Co., specializing in oncology, global product development, medical affairs, business development, and clinical pharmacology. He began his medical career as an intern and resident physician at Massachusetts General Hospital, Harvard Medical School.

Dr. Ramachandra earned his undergraduate degree in biochemistry, a PhD in experimental pathology (with a focus on chronic lymphocytic leukemia), and an MD from Rutgers University. He also holds an MBA from the Wharton School, University of Pennsylvania.

Dr. Gordon Ringold is currently CEO of Quadriga BioSciences, a clinical phase cancer biotech company developing a novel L-type Amino Acid Transporter 1 (LAT1) for delivering chemotherapeutic agents across the blood brain barrier and into rapidly growing cancer cells. He is also the Founder and Executive Chairman of Maxymune, a biopharma company developing differentiated treatments to transform the lives of those affected by serious immunological diseases. He is currently on the board of directors of Okava Pharmaceuticals. From 1997 to 2015, he served in various capacities as Co-Founder and/or CEO of Maxygen, SurroMed, Alexza, and Alavita. From 1991 to 2000, Dr. Ringold was CEO and Scientific Director of Affymax Research Institute (acquired by Glaxo in 1995) where he managed the development of novel technologies to accelerate the pace of drug discovery; prior to that he was VP and Director of the Institute for Cancer and Developmental Biology at Syntex Corporation (1986-1991).

Dr. Ringold received his Ph.D. in the laboratory of Dr. Harold Varmus (University of California, San Francisco), before joining the Stanford University School of Medicine, Department of Pharmacology (1978-1987). While on the Stanford faculty he invented technologies for manufacturing of recombinant proteins in mammalian cells, now widely used for production of dozens of therapeutic products and received the John J. Abel Award as the best Pharmacologist in the US under the age of 35. Dr. Ringold is an alumnus of Crown College, University of California, Santa Cruz, 1972.